Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.

Trial Profile

Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Dec 2009

At a glance

  • Drugs Bromfenac (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 07 Apr 2009 Planned end date changed from 1 Jan 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top